VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis

Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis

(2014) H.-R. Jiang et al.   JOURNAL OF IMMUNOLOGY

VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid

(2013) Erica K.M. Reeves et al.   BIOORGANIC & MEDICINAL CHEMISTRY

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects

(2013) Christopher R. Heier et al.   EMBO Molecular Medicine

T-cell response against varicella-zoster virus in fingolimod-treated MS patients

(2013) M. E. Ricklin et al.   NEUROLOGY

1,25-Dihydroxyvitamin D3 Suppresses TLR8 Expression and TLR8-Mediated Inflammatory Responses in Monocytes In Vitro and Experimental Autoimmune Encephalomyelitis In Vivo

(2013) Bo Li et al.   PLoS One

VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice

(2013) Jesse M. Damsker et al.   PLoS One

Regional Neural Activation Defines a Gateway for Autoreactive T Cells to Cross the Blood-Brain Barrier

(2012) Yasunobu Arima et al.   CELL

Recent Gains in Clinical Multiple Sclerosis Research

(2012) T. F. Runia et al.   CNS & Neurological Disorders-Drug Targets

Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab

(2012) B.K. Kleinschmidt-DeMasters et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Sudden unexpected death on fingolimod

(2012) JW Lindsey et al.   Multiple Sclerosis Journal

Effect of Inhaled Glucocorticoids in Childhood on Adult Height

(2012) H. William Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of external RNA controls for the standardisation of gene expression biomarker measurements

(2011) Alison S Devonshire et al.   BMC GENOMICS

Deregulated inflammasome signaling in disease

(2011) Mohamed Lamkanfi et al.   IMMUNOLOGICAL REVIEWS

IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination

(2011) Zhihua Ren et al.   JOURNAL OF NEUROIMMUNOLOGY

BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis

(2011) Xiaohui Zhou et al.   PLoS One

IL-7 Promotes TH1 Development and Serum IL-7 Predicts Clinical Response to Interferon-  in Multiple Sclerosis

(2011) L.-F. Lee et al.   Science Translational Medicine

Toll-like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease

(2010) Joseph M. Reynolds et al.   IMMUNITY

Meeting Report: Nuclear Receptors: Transcription Factors and Drug Targets Connecting Basic Research with Translational Medicine

(2010) Jan Tuckermann et al.   MOLECULAR ENDOCRINOLOGY

CCL5, CXCL10 and CXCL11 Chemokines in Patients with Active and Stable Relapsing-Remitting Multiple Sclerosis

(2010) Adam Szczuciński et al.   NEUROIMMUNOMODULATION

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of acute exacerbations in multiple sclerosis

(2009) AlexD Rae-Grant et al.   Annals of Indian Academy of Neurology

A robust in vitro screening assay to identify NF-κB inhibitors for inflammatory muscle diseases

(2009) Andreas R. Baudy et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE

(2009) Andrea Reboldi et al.   NATURE IMMUNOLOGY

Antagonism of the Chemokine Receptors CXCR3 and CXCR4 Reduces the Pathology of Experimental Autoimmune Encephalomyelitis

(2008) Rachel E. Kohler et al.   BRAIN PATHOLOGY

Interferon-β treatment for relapsing multiple sclerosis

(2008) Bianca Weinstock-Guttman et al.   EXPERT OPINION ON BIOLOGICAL THERAPY